Actinium expands patent coverage over iomab-act, its next-generation targeted radiotherapy conditioning agent, for gene edited stem cell-based therapies for non-malignant indications

-       newly issued u.s. patent augments actinium's existing composition of matter patent coverage over iomab-b and iomab-act targeted radiotherapy conditioning programs -       pertains to the use of iomab-act with genetically engineered hematopoietic stem cells for treating non-malignant diseases including sickle cell disease, severe combined immunodeficiency disease, Β-thalassemia and fanconi's anemia new york , aug. 1, 2024 /prnewswire/ -- actinium pharmaceuticals, inc. (nyse american: atnm) (actinium or the company), a leader in the development of antibody radiation conjugates (arcs) and other targeted radiotherapies, today announced the issuance of u.s. patent no. 11,912,780 titled, "anti-cd45-based conditioning methods and uses thereof in conjunction with gene-edited cell based therapies" by the united states patent and trademark office (uspto).
ACT Ratings Summary
ACT Quant Ranking